Efficacy of zenocutuzumab in NRG1 fusion-positive cancer

A basket study evaluated the efficacy of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with solid tumors harboring NRG1 fusions. Among 158 patients, 30% had a response (including 42% with pancreatic cancer).

Saved in:

Bibliographic Details
Main Authors:	Schram, Alison (Author) , Goto, Koichi (Author) , Kim, Dong-Wan (Author) , Macarulla, Teresa (Author) , Hollebecque, Antoine (Author) , O’Reilly, Eileen M. (Author) , Ou, Sai-Hong Ignatius (Author) , Rodon, Jordi (Author) , Rha, Sun Young (Author) , Nishino, Kazumi (Author) , Duruisseaux, Michaël (Author) , Park, Joon Oh (Author) , Neuzillet, Cindy (Author) , Liu, Stephen V. (Author) , Weinberg, Benjamin A. (Author) , Cleary, James M. (Author) , Calvo, Emiliano (Author) , Umemoto, Kumiko (Author) , Nagasaka, Misako (Author) , Springfeld, Christoph (Author) , Bekaii-Saab, Tanios (Author) , O’Kane, Grainne M. (Author) , Opdam, Frans (Author) , Reiss, Kim A. (Author) , Joe, Andrew K. (Author) , Wasserman, Ernesto (Author) , Stalbovskaya, Viktoriya (Author) , Ford, Jim (Author) , Adeyemi, Shola (Author) , Jain, Lokesh (Author) , Jauhari, Shekeab (Author) , Drilon, Alexander (Author)
Format:	Article (Journal)
Language:	English
Published:	February 5, 2025
In:	The New England journal of medicine Year: 2025, Volume: 392, Issue: 6, Pages: 566-576
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2405008
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa2405008 Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2405008
Author Notes:	Alison M. Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii-Saab, Grainne M. O’Kane, Frans Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, and Alexander Drilon, for the eNRGy Investigators

Description
Summary:	A basket study evaluated the efficacy of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with solid tumors harboring NRG1 fusions. Among 158 patients, 30% had a response (including 42% with pancreatic cancer).
Item Description:	Gesehen am 09.12.2025
Physical Description:	Online Resource
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2405008